Bullish
H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33
H.C. Wainwright analyst Robert Burns has raised the price target for Aktis Oncology (AKTS) from $30 to $33, maintaining a Buy rating. This decision is...